Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info

Executive Summary

A look at the status of suits involving Remicade, Neulasta, Epogen and Enbrel proposed biosimilars; Humira patents are being challenged in inter partes review proceedings rather than district court.

Advertisement

Related Content

Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira
Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
Sandoz's Biosimilar Rejection Ups Risks, But Won't Kill Market
Biosimilar Advisory Committee Features Actual Debate About Biosimilarity
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Biosimilar Launch Notification Delay Remains In The US, Might Not Matter For Newer Products
Biosimilar Battle Plans: US Supreme Court Seeks Solicitor General's Views On Zarxio
Sandoz Skips Enbrel Biosimilar Patent Dance, Spurs Infringement Suit
New Patent Battleground: Inter Partes Reviews Besiege Innovators
Neulasta Biosimilar: Smooth Patent Dance, Stumble On Launch Notification

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS118827

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel